Market Research Logo

United States Microbiology Culture Market Outlook to 2024

United States Microbiology Culture Market Outlook to 2024

Summary

GlobalData’s new report, United States Microbiology Culture Market Outlook to 2024, provides key market data on the United States Microbiology Culture market. The report provides value, in millions of US dollars within market segments - Bacterial Identification & Susceptibility Testing, Blood Culture, Immunological Culture Identification, Microbiology Analyzers, Mycobacteria Culture, Mycology Culture and Parasitology Culture

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Microbiology Culture market segments - Bacterial Identification & Susceptibility Testing, Blood Culture, Immunological Culture Identification, Microbiology Analyzers, Mycobacteria Culture, Mycology Culture and Parasitology Culture
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
  • 2017 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the United States Microbiology Culture market.
  • Key players covered include Becton Dickinson and Co, bioMerieux SA, Bio-Rad Laboratories Inc and Thermo Fisher Scientific Inc.
Reasons to buy
  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Microbiology Culture Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Microbiology Culture Market, United States
3.1 Microbiology Culture Market, United States, Revenue ($m), 2010-2017
3.2 Microbiology Culture Market, United States, Revenue ($m), 2017-2024
3.2.1 Bacterial Identification & Susceptibility Testing Market, United States, Revenue ($m), by Segment, 2010-2017
3.2.2 Microbiology Analyzers Market, United States, Revenue ($m), by Segment, 2010-2017
3.2.3 Bacterial Identification & Susceptibility Testing Market, United States, Revenue ($m), by Segment, 2017-2024
3.2.4 Microbiology Analyzers Market, United States, Revenue ($m), by Segment, 2017-2024
3.3 Microbiology Culture Market, United States, Distribution Share by Revenue ($m), 2017
3.4 Microbiology Culture Market, United States, Company Share by Revenue ($m), 2017
4 Overview of Key Companies in United States, Microbiology Culture Market
4.1 Becton Dickinson and Co
4.1.1 Company Overview
4.2 Thermo Fisher Scientific Inc
4.2.1 Company Overview
4.3 Beckman Coulter Inc
4.3.1 Company Overview
4.4 bioMerieux SA
4.4.1 Company Overview
4.5 Bio-Rad Laboratories Inc
4.5.1 Company Overview
4.6 Eiken Chemical Co Ltd
4.6.1 Company Overview
5 Financial Deals Landscape
5.1 Debt Offerings
5.1.1 LabCorp Raises USD600 Million in Public Offering of 3.25% Notes Due 2024
5.1.2 LabCorp Raises USD600 Million in Public Offering of 3.6% Notes Due 2027
5.1.3 Thermo Fisher Scientific Raises USD750 Million in Public Offering of 4.1% Notes Due 2047
5.1.4 Thermo Fisher Scientific Raises USD750 Million in Public Offering of 3.2% Notes Due 2027
5.1.5 Thermo Fisher Scientific Raises USD573.3 Million in Public Offering of Floating Rate Notes Due 2019
5.1.6 Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.4% Notes Due 2026
5.1.7 Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.95% Notes Due 2029
5.1.8 Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 2.875% Notes Due 2037
5.1.9 Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million
5.2 Equity Offerings
5.2.1 Thermo Fisher Scientific Prices Public Offering of Shares for USD1.5 Billion
5.3 Partnerships
5.3.1 OpGen Enters into Research Agreement with Merck
5.4 Private Equity
5.4.1 Weihai Weigao Equity Investment Management Acquires Rad Source Technologies
5.4.2 Essex Woodlands Management Invests Additional USD15 Million in Metabolon
6 Recent Developments
6.1 Corporate Communications
6.1.1 Sep 22, 2017: Neogen announces management change
6.1.2 Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer
6.1.3 Jul 18, 2017: LabCorp’s William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center
6.1.4 Jul 17, 2017: Neogen names new CEO
6.1.5 May 17, 2017: Advanced Instruments Announces Appointment of Byron Selman as CEO
6.1.6 Apr 11, 2017: Organovo Announces CEO Transition
6.1.7 Mar 29, 2017: LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two Primary Business Segments
6.1.8 Mar 01, 2017: Thermo Fisher Scientific Elects New Director to Board
6.1.9 Jan 26, 2017: Metabolon Announces Changes to Executive Leadership Team
6.1.10 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe
6.1.11 Dec 07, 2016: Neogen names chief science officer
6.2 Financial Announcements
6.2.1 Oct 25, 2017: LabCorp Announces Record Third Quarter Results and Increases 2017 Guidance
6.2.2 Oct 25, 2017: Thermo Fisher Scientific Reports Third Quarter 2017 Results
6.2.3 Oct 04, 2017: Organovo Announces Preliminary Fiscal Second-Quarter Total Revenue; Company Restructures to Improve Operational Efficiency
6.2.4 Sep 19, 2017: Neogen reports 21% net income increase
6.2.5 Aug 09, 2017: Organovo Announces Fiscal First-Quarter 2018 Results; Company Affirms Full-Year Fiscal 2018 Outlook
6.2.6 Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance
6.2.7 Jul 26, 2017: Thermo Fisher Scientific Reports Second Quarter 2017 Results
6.2.8 Jul 26, 2017: Quidel Reports Second Quarter 2017 Financial Results
6.2.9 Jul 18, 2017: Neogen reports record revenues and earnings
6.2.10 Jul 12, 2017: Premaitha Health: Investment Agreement Extension with Thermo Fisher Scientific
6.2.11 Jun 07, 2017: Organovo Announces Fiscal Fourth-Quarter and Full-Year 2017 Results; Company Issues Full-Year Fiscal 2018 Outlook
6.2.12 Jun 01, 2017: Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan
6.2.13 Apr 26, 2017: Thermo Fisher Scientific Reports First Quarter 2017 Results
6.2.14 Apr 25, 2017: Laboratory Corporation of America Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance
6.2.15 Apr 24, 2017: Quidel Reports First Quarter 2017 Financial Results
6.2.16 Mar 22, 2017: Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554
6.2.17 Mar 21, 2017: Neogen reports 24% increase in net income
6.2.18 Mar 13, 2017: DJO Global Announces The Launch of The AltiVate Anatomic Shoulder System
6.2.19 Feb 16, 2017: Laboratory Corporation of America Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance
6.2.20 Feb 09, 2017: Organovo Announces Fiscal Third-Quarter 2017 Results
6.2.21 Feb 08, 2017: Quidel Reports Fourth Quarter and Full Year 2016 Financial Results
6.2.22 Jan 31, 2017: Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2016 Results
6.2.23 Jan 18, 2017: Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
6.2.24 Jan 18, 2017: Teva Receives FDA Approval for VANTRELA ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated with Proprietary Abuse Deterrence Technology
6.2.25 Jan 18, 2017: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study
6.2.26 Jan 17, 2017: Encore Dermatology Announces Launch of Tridesilon (desonide) Cream, 0.05%
6.2.27 Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board
6.2.28 Jan 06, 2017: Quidel Announces Preliminary Revenue for Fourth Quarter 2016
6.2.29 Dec 24, 2016: Genor Biopharma's PD-1 antibody Genolimzumab got clinical trial approval from the CFDA
6.2.30 Dec 21, 2016: Notice Concerning the Phase I Clinical Study on NC-6004 for Patients with Head and Neck Cancer in Japan
6.2.31 Dec 21, 2016: Neogen reports 23% increase in net income
6.2.32 Nov 03, 2016: Organovo Announces Fiscal Second-Quarter 2017 Results; Company Affirms Full-Year Fiscal 2017 and Long-Range Outlook
6.3 Legal And Regulatory
6.3.1 Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
6.3.2 Jan 23, 2017: ISO 17025 Accreditation for Microbiology Manufacturing Site Offers Increased Confidence to Microbiology Testing Laboratories
6.3.3 Nov 29, 2016: C3 Jian announces names change to C3J Therapeutics
6.3.4 Nov 29, 2016: C3 Jian Announces Corporate Name Change and Expansion of Management Team
6.4 Other Significant Developments
6.4.1 Sep 25, 2017: LabCorp Objects to Proposed PAMA 2018 Medicare Payment Rates for Clinical Laboratory Tests; Calls for Delay in Implementation to Avoid Significant Harm to Medicare Beneficiaries
6.4.2 Jul 18, 2017: BD Transforms Microbiology Urine Testing
6.4.3 Jan 23, 2017: Quidel Announces Modification of Revenue Reporting Categories
6.5 Product News
6.5.1 Apr 05, 2017: Pall Fortebio Launches the Octet Red96E System For More Versatile Biologics Characterization
6.6 Strategy And Business Planning
6.6.1 Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK
7 Appendix
7.1 Research Methodology
7.1.1 Coverage
7.1.2 Secondary Research
7.1.3 Primary Research
7.1.4 Market Modeling and Forecasting
7.1.5 Company Share Analysis
7.1.6 Distribution Share Analysis
7.1.7 Benchmarking
7.2 GlobalData Consulting
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Microbiology Culture Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017
Table 2: Microbiology Culture Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024
Table 3: Bacterial Identification & Susceptibility Testing Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017
Table 4: Microbiology Analyzers Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017
Table 5: Bacterial Identification & Susceptibility Testing Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024
Table 6: Microbiology Analyzers Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024
Table 7: Microbiology Culture Market, United States, Distribution Share by Revenue ($m), USD Constant, 2017
Table 8: Microbiology Culture Market, United States, Company Share by Revenue ($m), USD Constant, 2017
Table 9: LabCorp Raises USD600 Million in Public Offering of 3.25% Notes Due 2024
Table 10: LabCorp Raises USD600 Million in Public Offering of 3.6% Notes Due 2027
Table 11: Thermo Fisher Scientific Raises USD750 Million in Public Offering of 4.1% Notes Due 2047
Table 12: Thermo Fisher Scientific Raises USD750 Million in Public Offering of 3.2% Notes Due 2027
Table 13: Thermo Fisher Scientific Raises USD573.3 Million in Public Offering of Floating Rate Notes Due 2019
Table 14: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.4% Notes Due 2026
Table 15: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.95% Notes Due 2029
Table 16: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 2.875% Notes Due 2037
Table 17: Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million
Table 18: Thermo Fisher Scientific Prices Public Offering of Shares for USD1.5 Billion
Table 19: OpGen Enters into Research Agreement with Merck
Table 20: Weihai Weigao Equity Investment Management Acquires Rad Source Technologies
Table 21: Essex Woodlands Management Invests Additional USD15 Million in Metabolon
Table 22: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country
1.2 List of Figures
Figure 1: Microbiology Culture Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017
Figure 2: Microbiology Culture Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024
Figure 3: Bacterial Identification & Susceptibility Testing Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017
Figure 4: Microbiology Analyzers Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017
Figure 5: Bacterial Identification & Susceptibility Testing Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024
Figure 6: Microbiology Analyzers Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024
Figure 7: Microbiology Culture Market, United States, Company Share (%) 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report